{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:07:30Z","timestamp":1740107250544,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00270-022-03314-9","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T22:09:00Z","timestamp":1669846140000},"page":"60-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of Non-tumoral Liver Dose with Treatment-Related Adverse Events in Patients with Hepatocellular Carcinoma Treated with Glass-Based Yttrium-90 Radioembolization"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0884-959X","authenticated-orcid":false,"given":"Linzi A.","family":"Webster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzhi","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill S.","family":"Majdalany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary L.","family":"Bercu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mircea M.","family":"Cristescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoram","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed F.","family":"Loya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"1","key":"3314_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3314_CR2","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.21037\/jgo-20-435","volume":"12","author":"RM Shah","year":"2021","unstructured":"Shah RM, et al. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. J Gastrointest Oncol. 2021;12(4):1718\u201331.","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"3314_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","volume":"36","author":"LE Moreno-Luna","year":"2013","unstructured":"Moreno-Luna LE, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(3):714\u201323.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"3314_CR4","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","volume":"22","author":"C Lance","year":"2011","unstructured":"Lance C, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(12):1697\u2013705.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"3314_CR5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741\u20139.","journal-title":"Hepatology"},{"issue":"2","key":"3314_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497-507.e2.","journal-title":"Gastroenterology"},{"issue":"2","key":"3314_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"A El Fouly","year":"2015","unstructured":"El Fouly A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35(2):627\u201335.","journal-title":"Liver Int"},{"issue":"2","key":"3314_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"3314_CR9","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain H, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"3314_CR10","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1148\/rg.2015140314","volume":"35","author":"JC Camacho","year":"2015","unstructured":"Camacho JC, et al. (90)Y Radioembolization: multimodality imaging pattern approach with angiographic correlation for optimized target therapy delivery. Radiographics. 2015;35(5):1602\u201318.","journal-title":"Radiographics"},{"key":"3314_CR11","unstructured":"Package Insert: TheraSphere Yttrium-90 Glass Microspheres. [cited 6 February 2022]; https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi_h-qxxuz1AhVkjYkEHSDnBocQFnoECAMQAQ&url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fcdrh_docs%2Fpdf%2Fh980006c.pdf&usg=AOvVaw3DTs9oqnqZ43-boZ5FwCzu."},{"issue":"5","key":"3314_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jvir.2020.12.023","volume":"32","author":"A Villalobos","year":"2021","unstructured":"Villalobos A, et al. Tumor-to-normal ratio relationship between planning technetium-99 macroaggregated albumin and posttherapy Yttrium-90 Bremsstrahlung SPECT\/CT. J Vasc Interv Radiol. 2021;32(5):752\u201360.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3314_CR13","first-page":"11s","volume":"40","author":"WE Bolch","year":"1999","unstructured":"Bolch WE, et al. MIRD pamphlet No 17: the dosimetry of nonuniform activity distributions\u2013radionuclide S values at the voxel level medical internal radiation dose committee. J Nucl Med. 1999;40(1):11s\u201336s.","journal-title":"J Nucl Med"},{"issue":"3","key":"3314_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, et al. MIRD pamphlet No 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384.","journal-title":"J Nucl Med"},{"issue":"2","key":"3314_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00270-020-02638-8","volume":"44","author":"M Elsayed","year":"2021","unstructured":"Elsayed M, et al. Comparison of Tc-99m MAA planar versus SPECT\/CT imaging for lung shunt fraction evaluation prior to Y-90 radioembolization: are we overestimating lung shunt fraction? Cardiovasc Intervent Radiol. 2021;44(2):254\u201360.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3314_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109698","volume":"139","author":"K Kne\u0161aurek","year":"2021","unstructured":"Kne\u0161aurek K. An estimate of (90)Y dosimetry for bremsstrahlung SPECT\/CT imaging in liver therapy with (90)Y microspheres. Eur J Radiol. 2021;139: 109698.","journal-title":"Eur J Radiol"},{"issue":"5","key":"3314_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/acm2.12400","volume":"19","author":"PS Potrebko","year":"2018","unstructured":"Potrebko PS, et al. SPECT\/CT image-based dosimetry for Yttrium-90 radionuclide therapy: application to treatment response. J Appl Clin Med Phys. 2018;19(5):435\u201343.","journal-title":"J Appl Clin Med Phys"},{"issue":"supplement 2","key":"3314_CR18","first-page":"306","volume":"57","author":"A Nelson","year":"2016","unstructured":"Nelson A, Swallen A, Dewaraja Y. Evaluation of a voxel-based yttrium-90 (Y-90) dose calculation method for Bremsstrahlung SPECT using a liver phantom. J Nucl Med. 2016;57(supplement 2):306\u2013306.","journal-title":"J Nucl Med"},{"key":"3314_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110865","volume":"132","author":"A Skanjeti","year":"2020","unstructured":"Skanjeti A, et al. Selective internal radiation therapy of hepatic tumors: morphologic and functional imaging for voxel-based computer-aided dosimetry. Biomed Pharmacother. 2020;132: 110865.","journal-title":"Biomed Pharmacother"},{"issue":"19","key":"3314_CR20","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.3390\/cancers13194908","volume":"13","author":"T Sankhla","year":"2021","unstructured":"Sankhla T, et al. Role of resin microsphere y90 dosimetry in predicting objective tumor response, survival and treatment related toxicity in surgically unresectable colorectal liver metastasis: a retrospective single institution study. Cancers (Basel). 2021;13(19):4908.","journal-title":"Cancers (Basel)."},{"key":"3314_CR21","unstructured":"Program, N.C.T.E. Common terminology criteria for adverse events (CTCAE). 2020 [cited 6 February 2022]; https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"issue":"6","key":"3314_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"3314_CR23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00259-013-2395-x","volume":"40","author":"E Garin","year":"2013","unstructured":"Garin E, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"3314_CR24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1007\/s00259-015-3068-8","volume":"42","author":"C Chiesa","year":"2015","unstructured":"Chiesa C, et al. Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3314_CR25","first-page":"101","volume":"37","author":"E Garin","year":"2017","unstructured":"Garin E, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver Int official J Int Assoc Study Liver. 2017;37(1):101\u201310.","journal-title":"Liver Int official J Int Assoc Study Liver"},{"issue":"9","key":"3314_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00270-018-1949-5","volume":"41","author":"KT Chan","year":"2018","unstructured":"Chan KT, et al. Hepatotoxic dose thresholds by positron-emission tomography after yttrium-90 radioembolization of liver tumors: a prospective single-arm observational study. Cardiovasc Intervent Radiol. 2018;41(9):1363\u201372.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3314_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1477-7819-6-93","volume":"6","author":"CD South","year":"2008","unstructured":"South CD, et al. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol. 2008;6:93.","journal-title":"World J Surg Oncol"},{"issue":"9","key":"3314_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jvir.2009.05.030","volume":"20","author":"A Riaz","year":"2009","unstructured":"Riaz A, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20(9):1121\u201330.","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"3314_CR29","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"3314_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jvir.2013.04.018","volume":"24","author":"SA Padia","year":"2013","unstructured":"Padia SA, et al. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. J Vasc Interv Radiol. 2013;24(8):1147\u201353.","journal-title":"J Vasc Interv Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-022-03314-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T16:08:03Z","timestamp":1672762083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-022-03314-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3314"],"URL":"https:\/\/doi.org\/10.1007\/s00270-022-03314-9","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"type":"print","value":"0174-1551"},{"type":"electronic","value":"1432-086X"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"9 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nima Kokabi, MD, receives research support from SIRtex Medical. Nima Kokabi, MD receives educational grant from Boston Scientific. Bill S. Majdalany, MD, serves on the scientific advisory board of Balt Medical. The remaining authors have no conflicts of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was IRB-approved, and, due to the retrospective nature of this work, no formal consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}